Amgen Inc.

Epiodyne, Inc.

Yihong Li

Julio Cesar Medina

Xiaodong Wang

Jason A Duquette

Ana Zurisadai Gonzalez Buenrostro

Daqing Sun

Xuelei Yan

Yosup Rew

Steven H Olson

Lawrence R McGee

Pingyu Ding

Frank Kayser

Xiaoqi Chen

Thomas T Nguyen

Jeffrey Thomas Mihalic

Zhihua Ma

David John Kopecky

Michael G Johnson

Felix Gonzalez Lopez De Turiso

Brian M Fox

Michael D Bartberger

John Eksterowicz

Hilary Plake Beck

Richard V Connors

Jeffrey Deignan

Julie Anne Heath

Darin J Gustin

Zhihong Li

Joel McIntosh

Jiasheng Fu

Zhi-Liang Wei

Ulhas Bhatt

Philip M Roveto

Alok Nerurkar

Frederick Seidl

Dustin L McMinn

Ming Yu

Zice Fu

Jonathan Dante Low

Jiwen Liu

Brian Stuart Lucas

Yingcai Wang

XianYun Jiao

Tien Widjaja

Xin Huang

Michael W Gribble, Jr

Jiang Zhu

SuJen Lai

Benjamin Fisher

Martin Holan

John Lee

Heng Cheng

Corinne Sadlowski

Sean P Brown

Gwenaella Rescourio

Mike Elias Lizarzaburu

Michael J Schmitt

Malgorzata Wanska

David Sperandio

Christine Weathers

Steven Howard Olson

Salman Yojiro Jabri

Scott Preston Simonovich

Dustin Mcminn

Jr Michael William Gribble

Larry Mcgee

Hilary Place Beck

Xianjun Jiao

Darin James Gustin

Michael Johnson

Mike Lizarzaburu

Jeffery Deignan

Sujen Lai

Philip Marley Roveto

Lawrence Mcgee

Jr Gribble

Xianyun Jiao

Michael William Gribble

Brian Matthew Fox

Richard Victor Connors

Joel Mcintosh

Provided herein are opioid receptor modulators and pharmaceutical compositions comprising said compounds.

Opioid receptor modulators

Compounds are provided having the structure of Formula (I): or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof, wherein A, B, L, R, R, R, R, R, m and n are as defined herein. Such compounds modulate the opioid receptor, particulare the mu-opioid receptor (MOR) and/or the kappa-opioid receptor (KOR), and/or the delta-opioid receptor (DOR). Products containing such compounds, as well as methods for their use and preparation, are also provided.

Opioid receptor modulators and products and methods related thereto

Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, or a stereoisomer thereof; and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer. 

Alpha-hydroxy phenylacetic acid pharmacophore or bioisostere Mcl-1 protein antagonists

The present invention provides MDM2 inhibitor compounds of Formula (I), or the pharmaceutically acceptable salts thereof, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor of Formula (I). 

Heteroaryl acid morpholinone compounds as MDM2 inhibitors for the treatment of cancer

The present invention provides MDM2 inhibitor compounds of Formula I, 

Piperidinone derivatives as MDM2 inhibitors for the treatment of cancer

The present invention provides MDM2 inhibitor compounds of Formula I or II, or the pharmaceutically acceptable salts thereof, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.

Heterocyclic compounds as MDM2 inhibitors for the treatment of cancer

Growing community of inventors

Millbrae, CA, United States of America

Yihong Li